Loading NVS detail
Loading ticker data...
Loading NVS detail
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.
The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Chart data unavailable
East Hanover, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as public health efforts against chronic diseases slow or reverse in many countries.1 Three distinct Novartis community health approaches focused on closing gaps in care for low-income, rural and other communities will nearly triple from 11 to more than 30 countries by 2030, including:
Basel, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as public health efforts against chronic diseases slow or reverse in many countries.1 Three distinct Novartis community health approaches focused on closing gaps in care for low-income, rural and other communities will nearly triple from 11 to more than 30 countries by 2030, including:
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Eldred Rock Partners LLC reduced its position in shares of Novartis AG (NYSE: NVS) by 10.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,549 shares of the company's stock after selling 9,204 shares during the period. Novartis makes
Boston Common Asset Management LLC decreased its stake in shares of Novartis AG (NYSE: NVS) by 8.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,266 shares of the company's stock after selling 10,970 shares during the
Euro Pacific Asset Management LLC lessened its holdings in shares of Novartis AG (NYSE: NVS) by 54.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,231 shares of the company's stock after selling 49,536 shares during the quarter. Euro Pacific Asset Management
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney outcomes over two years, demonstrating a slowing of disease progression and the potential to preserve kidney function in IgAN1. The results were published in the New England Journal of Medicine and simultaneously presented as late‑breaking data at the 2026 World Congress of Nephrology (WCN).
Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.
Novartis AG (ADR) (NYSE:NVS) announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for allergic diseases. Under the agreement, Novartis will pay up to US$2 billion in upfront and milestone payments for Excellergy.
Expense, risk, and sector focus set these two ETFs apart-see which aligns better with your global investing strategy.
Novartis (NVS, Financials) agreed to buy Excellergy, a biotech company located in the U.S., for up to $2 billion. This is part of a string of recent investments
Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Therapeutics for up to $3 billion to secure the rights to an experimental breast cancer drug.
Novartis AG (ADR) (NYSE:NVS) announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for...
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
Swiss pharma company Novartis said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion.
